STOCK TITAN

EVOFEM BIOSCIENCE INC - EVFM STOCK NEWS

Welcome to our dedicated page for EVOFEM BIOSCIENCE news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on EVOFEM BIOSCIENCE stock.

Evofem Biosciences, Inc. (OTCQB: EVFM) is a pioneering biotechnology company dedicated to enhancing women's reproductive health across the globe. The company's flagship product, Phexxi® (lactic acid, citric acid, and potassium bitartrate), is an FDA-approved, hormone-free contraceptive gel. Applied 0-60 minutes before sex, Phexxi maintains the vagina's natural pH, creating an environment unsuitable for sperm. This innovative product has seen increased sales and usage each year since its launch in 2020.

Evofem is committed to providing woman-controlled, non-invasive, and reversible reproductive health solutions. The company's recent strategic initiatives include securing expanded Medicaid coverage in Washington State and renegotiating rebates with Medi-Cal in California. These moves have made Phexxi more accessible to millions of women on state healthcare plans.

In December 2023, Evofem entered a definitive agreement to be acquired by Aditxt, Inc. (Nasdaq: ADTX). This acquisition is expected to accelerate Evofem's growth and expand its product portfolio. The company anticipates this merger will close in the second half of 2024.

Financially, Evofem continues to show resilience and growth. In 2023, the company reported $18.2 million in net sales and a significant reduction in operating expenses. Despite challenges like a cyberattack and ongoing austerity measures, Evofem expects its fourth consecutive year of sales growth in 2024.

Looking forward, Evofem is poised to benefit from the burgeoning use of GLP-1 receptor agonists, which can reduce the effectiveness of oral contraceptives. As a non-hormonal contraceptive, Phexxi offers a critical alternative for women using these medications. Evofem's innovations and strategic partnerships underscore its commitment to addressing unmet needs in women's health.

Rhea-AI Summary

Evofem Biosciences (Nasdaq: EVFM) has appointed Karina Fedasz as its new Head of Business Development, effective immediately. Her role focuses on expanding markets for Phexxi, Evofem's first-in-class hormone-free contraceptive. Fedasz brings extensive experience in deal-making and partnerships, having previously executed significant global deals. The company aims to enhance access to Phexxi both domestically and internationally. Evofem is set to report its first-quarter results on May 4, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
none
-
Rhea-AI Summary

Evofem Biosciences, Inc. (Nasdaq: EVFM) has received approval from the Nasdaq Hearings Panel to continue its listing while awaiting shareholder vote on a proposed reverse stock split. This vote is scheduled for May 4, 2022. The proposed split ratio ranges from 1-for-5 to 1-for-15 shares. This action aims to ensure compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as the company received a deficiency letter in August 2021. The company must regain compliance by May 20, 2022, or risk delisting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.54%
Tags
none
-
Rhea-AI Summary

Evofem Biosciences (Nasdaq: EVFM) announced significant findings from the Phase 2B/3 AMPREVENCE clinical trial, showcasing a 50% reduction in chlamydia and a 78% reduction in gonorrhea among women using EVO100 (investigational name for Phexxi). The trial involved 860 females aged 18-45 with prior infections. Additionally, patient satisfaction data were collected, contributing to the ongoing EVOGUARD Phase 3 trial, with topline results expected in late 2022. These findings aim to enhance access for EVO100 if approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
none
Rhea-AI Summary

Evofem Biosciences has completed enrollment in the EVOGUARD Phase 3 clinical trial for EVO100 (Phexxi) targeting prevention of chlamydia and gonorrhea among women. The trial exceeded its initial enrollment goal, reaching 1,903 participants, allowing for robust data collection. Top-line results are anticipated in late 2022. The FDA's QIDP designation for EVO100 may provide five additional years of exclusivity, and there is a noted need for new preventive options in light of rising infection rates. The complete trial outcome could significantly influence women's sexual health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.2%
Tags
-
Rhea-AI Summary

Evofem Biosciences, Inc. (Nasdaq: EVFM) reported strong growth for Q4 2021, with net product sales rising 109% to $3.6 million, largely due to a 73% increase in Phexxi units shipped. The company reduced its cash burn rate to $16.8 million from $32.0 million in Q3. Evofem also completed enrollment in its Phase 3 clinical trial for Phexxi, targeting new indications against chlamydia and gonorrhea, expecting to submit data to the FDA in early 2023. The total operating expenses for Q4 were $41.0 million, down from $45.1 million in Q3.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.2%
Tags
-
Rhea-AI Summary

Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on March 3, 2022, at 4:30 p.m. ET to discuss its financial results and business highlights for Q4 and the year ended December 31, 2021. Interested parties can access the live and archived webcast through the company's investor room. The conference call can be joined via phone, with a replay available for 24 hours post-call. Evofem is focused on developing innovative women's sexual and reproductive health products, including the FDA-approved contraceptive gel, Phexxi®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
conferences
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) announced FDA's "Qualified Infectious Disease Product" (QIDP) designation for EVO100, aimed at preventing urogenital chlamydia in women, marking a potential new indication in clinical development. The company is preparing for top-line data from the Phase 3 EVOGUARD trial in Q3 2022, with positive results likely supporting FDA submission early in 2023. The QIDP designation grants five additional years of marketing exclusivity upon approval, catering to the significant unmet need for STI prevention as no FDA-approved products currently exist.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
none
-
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) will present at the Aegis Virtual Conference on February 23, 2022, at 4:30 p.m. ET. The webcast can be accessed via this link or on Zoom. Evofem is known for its innovative products in women's sexual and reproductive health, including Phexxi®, a hormone-free contraceptive vaginal gel. Phexxi® aims to address unmet needs in contraception and protection against STIs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
conferences
-
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) reported strong preliminary results for Q4 2021, achieving $3.5 million in net product sales, more than double Q3 sales. Key metrics included an 81% increase in dispensed Phexxi boxes and a 69% rise in total prescriptions filled. The company also reduced its net cash burn from $32 million in Q3 to approximately $17 million. Additionally, Evofem raised $5 million in non-dilutive capital in January 2022 to support ongoing initiatives. The CEO highlighted strong demand for Phexxi, projecting positive impacts from recently issued government guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.92%
Tags
none
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) applauds recent guidance from HRSA and the U.S. Department of Labor, mandating coverage for FDA-approved contraceptives, including its product Phexxi, with no out-of-pocket costs for women. This guidance aims to enhance access to contraceptives under the Affordable Care Act, potentially benefiting millions of women. CEO Saundra Pelletier emphasized the positive impact on reducing unintended pregnancies and improving women's access to hormone-free birth control. The comprehensive coverage includes all FDA-approved contraceptives deemed medically necessary by healthcare providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
none

FAQ

What is the current stock price of EVOFEM BIOSCIENCE (EVFM)?

The current stock price of EVOFEM BIOSCIENCE (EVFM) is $0.0091 as of December 24, 2024.

What is the market cap of EVOFEM BIOSCIENCE (EVFM)?

The market cap of EVOFEM BIOSCIENCE (EVFM) is approximately 1.0M.

What is Evofem Biosciences known for?

Evofem Biosciences is known for developing innovative, hormone-free reproductive health products for women, including its flagship contraceptive gel, Phexxi®.

What is Phexxi?

Phexxi is a hormone-free, on-demand contraceptive vaginal gel that maintains the vaginal pH to create an environment unsuitable for sperm, preventing pregnancy.

How is Phexxi applied?

Phexxi is applied using pre-filled applicators 0-60 minutes before each act of sex to ensure effective contraception.

What recent achievements has Evofem Biosciences made?

Recent achievements include expanded Medicaid coverage for Phexxi in Washington State and renegotiated rebates with Medi-Cal in California, making Phexxi more accessible.

Is Evofem Biosciences undergoing any significant changes?

Yes, Evofem Biosciences has entered a definitive agreement to be acquired by Aditxt, Inc., which is expected to close in the second half of 2024.

How has Evofem Biosciences performed financially?

In 2023, Evofem reported $18.2 million in net sales and a significant reduction in operating expenses, indicating strong financial performance.

What are the future plans of Evofem Biosciences?

Evofem plans to continue growing Phexxi's market share, particularly among women using GLP-1 receptor agonists, and to expand its product portfolio post-acquisition by Aditxt, Inc.

How does Phexxi benefit women using GLP-1 receptor agonists?

GLP-1 receptor agonists can make oral contraceptives less effective, making Phexxi a valuable non-hormonal alternative for these women.

Where can I learn more about Evofem Biosciences and its products?

You can learn more about Evofem Biosciences and its products at phexxi.com and evofem.com.

What is the significance of Evofem's recent U.S. patent?

The recent U.S. patent for Phexxi covers its composition and methods for contraception, reinforcing the product's innovative approach and market position.

EVOFEM BIOSCIENCE INC

Nasdaq:EVFM

EVFM Rankings

EVFM Stock Data

1.00M
100.33M
0%
0.1%
10.98%
Biotechnology
Healthcare
Link
United States of America
San Diego